Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$204.76 USD

204.76
878,984

-0.06 (-0.03%)

Updated Aug 30, 2024 04:00 PM ET

After-Market: $204.61 -0.15 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Mark Vickery headshot

Top Research Reports for Barclays, Netflix and Nike

Today's Research Daily features new research reports on 16 major stocks, including Barclays (BCS), Netflix (NFLX) and NIKE (NKE).

    Biogen Presents Positive Early Data from Alzheimer's Study

    Last week, Biogen Inc. (BIIB) presented positive data from a phase I study (PRIME) on its anti-amyloid treatments in development, aducanumab, at the Clinical Trials on Alzheimer's Disease (CTAD) meeting in San Diego.

      Lilly/AstraZeneca Expand Alzheimer Disease Collaboration

      Eli Lilly and Company (LLY) and AstraZeneca plc (AZN) expanded their existing collaboration to develop the second treatment for Alzheimer's disease, MEDI1814

        Stock Market News for December 08, 2016

        The Trump induced rally continued to boost major benchmarks to finish at all-time record highs on Wednesday offsetting the decline in healthcare stocks.

          GW Pharmaceuticals (GWPH): What Awaits in Q4 Earnings?

          GW Pharmaceuticals (GWPH) is set to report fourth-quarter fiscal 2016 results on Dec 5. The company posted positive surprise of 57.80% in the last quarter.

            Arpita Dutt headshot

            Biotech Stock Roundup: Actelion Soars on Acquisition Talks, Another Clinical Hold for Juno

            With Johnson & Johnson eyeing Actelion (ALIOF), will mergers and acquisitions pick pace in the biotech sector?

              The Zacks Analyst Blog Highlights: Biogen, Honda, Intel, CSX and General Growth Properties

              The Zacks Analyst Blog Highlights: Biogen, Honda, Intel, CSX and General Growth Properties

                Sheraz Mian headshot

                Top Research Reports for Intel, Honda & Biogen

                Today's Research Daily features new research reports on 16 major stocks, including Biogen (BIIB), Honda (HMC) and Intel (INTC).

                  Company News for November 08, 2016

                  Companies in the News are: BRK.B,LC,BID,BIIB,IONS

                    Zacks Industry Outlook Highlights: Bristol-Myers, Biogen, Merck, Celgene and ARIAD Pharmaceuticals

                    Zacks Industry Outlook Highlights: Bristol-Myers, Biogen, Merck, Celgene and ARIAD Pharmaceuticals

                      Arpita Dutt headshot

                      Fundamentals Remain Strong in the Pharma Sector

                      We could see several M&A agreements being announced in the coming quarters, though companies are wary of bidding wars leading to over-priced deals.

                        Stock Market News for October 12, 2016

                        Disappointing start to the third quarter earnings season weighed on benchmarks on Tuesday

                          6 Healthcare Stocks Investors Cannot Miss in Q3 Earnings

                          A number of healthcare companies are recording improvements in their financial numbers.

                            Stock Market News for September 21, 2016

                            Benchmarks finished slightly higher on Tuesday ahead of the two-day policy meetings of the Fed and Bank of Japan (BOJ) ending today

                              Sheraz Mian headshot

                              Top 3 Research Reports for August 15, 2016

                              Today's must-read reports are for AstraZeneca (AZN), Caterpillar (CAT) and Exelon (EXC).

                                Sheraz Mian headshot

                                Fresh Research Reports For Intel (INTC), AT&T (T) & Others

                                Today's must-read reports are for Intel (INTC), Biogen (BIIB) and AT&T (T).

                                  Arpita Dutt headshot

                                  Pharma Industry Outlook: Fundamentals Remain Strong

                                  It's been a rough start to the year for pharma and biotech with several factors weighing on the sector.

                                    Stock Market News for July 07, 2016

                                    Benchmarks ended in the green on Wednesday after the FOMC minutes from June meeting showed that most of the Fed policymakers were in favor of keeping rates unchanged.

                                      Stock Market News for June 16, 2016

                                      Benchmarks ended in the red for the fifth consecutive session on Wednesday after the Fed opted to keep interest rate unchanged and raised concerns about number of hikes this year

                                        Stock Market News for May 10, 2016

                                        Benchmarks closed mixed on Monday after gains in healthcare stocks offset declines in energy stocks

                                          Arpita Dutt headshot

                                          Pharma Industry Stock Outlook - March 2016

                                          Looking at consensus earnings expectations, the Medical sector, which had performed well in 2015, is expected to see earnings growth of 0.7% and revenue growth of 7.7% in Q1.

                                            Arpita Dutt headshot

                                            Pharma Industry Stock Outlook - March 2016

                                            Looking at consensus earnings expectations, the Medical sector, which had performed well in 2015, is expected to see earnings growth of 0.7% and revenue growth of 7.7% in Q1.

                                              4 Biotech Stocks Looking Good this Earnings Season

                                              the market sentiment seems to be improving driven by upgraded guidance, product approvals and encouraging pipeline updates.

                                                4 Health Care Stocks to Watch Out for this Earnings Season

                                                Health care companies have been attracting a lot of attention lately.

                                                  The biotech segment has been growing well surpassing all expectations.